VERA Stock Summary and Trading Ideas (Vera Therapeutics - Class A | NASDAQ:VERA)

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Vera Therapeutics - Class A trades on the NASDAQ stock market under the symbol VERA.

As of August 27, 2026, VERA stock price declined to $35.19 with 2,162,143 million shares trading.

VERA has a beta of 0.86, meaning it tends to be less sensitive to market movements. VERA has a correlation of 0.03 to the broad based SPY ETF.

VERA has a market cap of $2.53 billion. This is considered a Mid Cap stock.

In the last 3 years, VERA traded as high as $56.05 and as low as $9.24.

The top ETF exchange traded funds that VERA belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.

VERA has outperformed the market in the last year with a price return of +56.1% while the SPY ETF gained +20.6%. However, in the short term, VERA had mixed performance relative to the market. It has underperformed in the last 3 months, returning +2.5% vs +2.9% return in SPY. But in the last 2 weeks, VERA shares have fared better than the market returning +17.3% compared to SPY -0.2%.

VERA support price is $35.38 and resistance is $38.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERA shares will trade within this expected range on the day.